

# Nexstim

## Nexstim Receives Therapy System Order from US Customer

Press release, Helsinki, 15 December 2025 at 9 AM (EET)

Nexstim Plc (“Nexstim” or the “Company”) has received an NBS 6 therapy system order from an U.S.-based customer that is acquiring the system for their second location.

FDA-cleared for the treatment of major depressive disorder (MDD) and for the pre-procedural mapping of the speech and motor cortices of the brain, the NBS 6 is a new-generation Nexstim system. It is built on Nexstim’s unique, clinically established E-field navigated TMS (transcranial magnetic stimulation) technology, with a modular system concept that allows system capabilities to expand over time and be highly customized based on a customer’s research or clinical interests. The new product generation reflects Nexstim’s advanced technological knowhow and persistent efforts in product development.

**Mikko Karvinen**, CEO of Nexstim, comments: *“We are delighted to partner with healthcare providers who share our commitment to excellence and innovation. The NBS 6 delivers exceptional value to our customers, helping hospitals and clinics achieve better outcomes for their patients. This order reinforces our dedication to supporting customers with superior technology and services.”*

Further information is available on the website [www.nexstim.com](http://www.nexstim.com), or by contacting:

**Mikko Karvinen**, CEO

+358 50 326 4101

[mikko.karvinen@nexstim.com](mailto:mikko.karvinen@nexstim.com)

### About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE-marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit [www.nexstim.com](http://www.nexstim.com)